For healthcare researchers and clinicians, this study underscores that body weight alone is an unreliable risk proxy in metabolic liver disease and points to an urgent need for refined diagnostic and monitoring strategies tailored to Asian populations.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide, but a critical blind spot has persisted: patients who are lean—those with a normal body mass index—have been widely assumed to carry lower risk. A major prospective multicohort study published in Gut now overturns that assumption, with direct implications for clinical practice and public health policy in China and beyond.
The researchers pooled data from three large cohorts—the UK Biobank, the Kailuan cohort, and the China Kadoorie Biobank—encompassing more than 186,000 individuals with MASLD, over 5,000 of whom were lean. After a median follow-up of 14.2 years, the results were stark. Lean patients with MASLD had more than double the risk of liver-related events (hazard ratio 2.14) and liver-related mortality (HR 2.31) compared to their non-lean counterparts. All-cause mortality and cardiovascular disease mortality were also significantly elevated, by 26% and 22% respectively.
Intriguingly, lean patients had a lower risk of incident cardiovascular disease overall, a finding that highlights the dissociation between hepatic and cardiovascular outcomes in this population. The study is notable not only for its size but for its inclusion of two large Chinese cohorts, making its conclusions directly applicable to the world’s largest population of MASLD patients.
For China’s healthcare system, where MASLD prevalence is rising rapidly due to dietary changes and sedentary lifestyles, the data carry a sobering message: lean individuals are not protected. Many may be overlooked by screening protocols that prioritize BMI or metabolic syndrome criteria. The findings argue for routine liver fibrosis assessment and closer monitoring in all MASLD patients, regardless of body habitus. For a researcher tracking China’s evolving disease burden, this study is a critical recalibration of a longstanding clinical assumption.
Why it matters:
This research directly challenges a widespread clinical bias that equates leanness with liver safety, revealing that lean MASLD patients harbor a more aggressive disease trajectory. For healthcare systems in China and across Asia, where lean MASLD prevalence is higher than in Western populations, the findings demand immediate revisions to risk stratification algorithms and surveillance guidelines.
ScientificChina — tracking what’s happening in Chinese science, technology, research, and industrial innovation in a way global professionals can actually use.
Follow ScientificChina for deeper insight into China’s evolving science, technology, and industrial landscape.
No products in the cart.